Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population
Authors' conclusion
In a large Dutch general RA population, the risk of cardiovascular events seems not to be different between JAKi users and those using bDMARDs, although a small increase in higher risk patients cannot be excluded.
Study context
- Population
- Rheumatoid arthritis (RA) patients starting a new bDMARD or Janus kinase inhibitors (JAKi) between 1 August 2018 and 31 January 2022, IQVIA's Dutch Real-World Data Longitudinal Prescription database (about 63% of outpatient prescriptions in the Netherlands)
- Participants
- 15,191 patients28,481 patient-years
- Exposure
- JAKi vs bDMARDs
- Outcome
- Cardiovascular event, defined as the start of platelet aggregation inhibitors during the study period
Methodological detailsmultilevel Poisson regression, adjusted for exposure time and confounders
- Multilevel Poisson regression
- Adjusted for exposure time and confounders
Main finding
Cardiovascular events
Adjusted incidence rate ratio
0.99
95% CI 0.70–1.41
Events by group
JAKivs bDMARDs
adjusted IRR 0.99 (95% CI 0.70–1.41)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Sub-analyses: patients >65 years, by sex, tofacitinib and baricitinib separately
- Yielded similar results
Original publication
Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population. Rheumatology (Oxford). Published 5 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →